DRUG-COATED balloon angioplasty has transformed the treatment of femoropopliteal artery disease, with evolving evidence supporting the safety of paclitaxel-coated devices while raising questions about their effectiveness in patients with advanced peripheral artery disease.
A recent chapter review examined the development of drug-coated balloon (DCB) technology, controversies surrounding paclitaxel safety, and emerging approaches involving sirolimus-based devices and intravascular imaging.
DCB angioplasty enables local delivery of antiproliferative medication to affected arteries without requiring permanent implantation of a vascular device.
Early-generation paclitaxel-based balloons demonstrated significant improvements in vessel patency and freedom from repeat intervention compared with conventional plain balloon angioplasty.
These benefits contributed to the widespread adoption of DCB technology for femoropopliteal artery disease, including interventions involving the superficial femoral artery.
However, concerns surrounding the long-term safety of paclitaxel-coated devices subsequently prompted renewed scrutiny of the technology.
In 2018, a meta-analysis identified an unexpected mortality signal associated with paclitaxel exposure, raising questions about the safety of drug-coated vascular devices.
The findings temporarily disrupted regulatory confidence and prompted further investigation into potential treatment-related risks.
Subsequent studies have reaffirmed the safety of paclitaxel-coated devices, addressing earlier concerns surrounding the reported mortality signal.
Nevertheless, questions remain regarding their clinical effectiveness in more advanced presentations of peripheral artery disease.
Recent trials have challenged the efficacy of paclitaxel-based DCB therapy, particularly among patients with chronic limb-threatening ischaemia.
These developments highlight the importance of distinguishing device safety from treatment effectiveness when evaluating endovascular interventions.
Although paclitaxel-coated balloons have demonstrated benefits over plain angioplasty, the review indicates that their performance in advanced disease warrants continued investigation.
Emerging developments in DCB technology are increasingly focused on alternative antiproliferative medications and improved procedural precision.
Sirolimus-based balloons represent one area of innovation, offering an alternative pharmacological approach to local drug delivery during endovascular treatment.
Alongside these developments, adjunctive intravascular imaging is being explored to improve procedural precision, safety, and drug delivery.
These strategies may contribute to further refinement of superficial femoral artery interventions as evidence surrounding existing technologies continues to evolve.
Overall, the review highlights the changing landscape of DCB therapy, with renewed confidence in paclitaxel safety accompanied by ongoing questions about efficacy in advanced disease.
Further evaluation of emerging drug formulations and imaging approaches will be important in determining their future role in endovascular treatment.
Reference
Arvanitis LV et al. The Role of Drug–Coated Balloon for the Treatment of Native Superficial Femoral Artery. In: Drug Coated Balloons. Cortese B.
Adobestock/damian
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
